Compare Novartis AG (NVS) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Petróleo Brasileiro SA — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Petróleo Brasileiro SA trades at $24.65 (market cap $151.94B). The key difference: Novartis AG is the larger of the two by market cap, and Petróleo Brasileiro SA pays the higher dividend (6.79%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Petróleo Brasileiro SA for 25 Days on average.
| NVS | PBR | |
|---|---|---|
Market Cap | $268.57B | $151.94B |
Volume | 1,532,573 | 30,240,092 |
Sector | Health | Energy |
52-Week High | $168.62 | $24.69 |
52-Week Low | $121.80 | $11.54 |
Typical Hold Time | 82 Days | 25 Days |
Enterprise Value | $309.89B | $212.36B |
Dividend Yield | 3.31% | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Petrobras (PBR) trades at $23.99, up 0.8% today, with a bullish technical signal from moving averages and strong fundamental metrics including a P/E of 6.24 and net income margin of 24.52%. Recent news highlights a new oil discovery off Amapa and the deployment of the P-80 platform, supporting production growth. Cash flow from operations remains robust at $36.05 billion for 2025, though 2026 projections show a net cash outflow.
The outlook is positive given low valuations, high profitability, and strategic expansions, but risks include volatile oil prices and political influence in Brazil. Analysts are generally bullish with a 50% buy rating and a consensus price target of $22.33, slightly below the current price, indicating potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
